Table 1.

Cost-Effectiveness Analysis: Number of Participants, Measure Used as Basis for ICER Calculations, ICER in 2014 Adjusted US Dollars, Cost-Effectiveness on the Basis of the ICER and the Definition Used in This Review, and Original Authors' Conclusion About Cost-Effectivenessa

  • a ICER=incremental cost-effectiveness ratio; EG=experimental group; VAS=visual analog scale; RMDQ=Roland-Morris Disability Questionnaire; RDQ=Roland Disability Questionnaire; ODI=Oswestry Disability Index; ISS=impairment-level sum score; EQ-5D=European Quality of Life–5 Dimensions, a health-related quality-of-life measure; SPADI=Shoulder Pain and Disability Index; SF-36=36-Item Short-Form Health Survey; AQOL=assessment of quality of life; QALY=quality-adjusted life year; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; LBP=low back pain; PTA=percutaneous transluminal angioplasty; MSC=musculoskeletal condition.

  • b A negative value for ICER indicates a result in favor of the intervention program, except when usual care was more effective on health than the intervention. In this case, a negative value of the ICER indicates a result in disfavor of the intervention program. These cases are marked with the symbol (*). “Direct” indicates that only costs directly imputable to health treatments were included in the computation, whereas “societal” means that other elements (eg, sick leave from paid work) are taken into account.

  • c Plus sign (+) indicates a cost-effective intervention using the definition of the present review, and minus sign (−) indicates a non–cost-effective intervention.